FIG 2.
DRD biomarker status for individual patients (columns) for %LOH and designated somatic genes in patients allocated to (A) rucaparib or (B) placebo. %LOH, percent genome-wide loss of heterozygosity; DRD, DNA repair deficiency.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.